IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
13 Septiembre 2023 - 7:30AM
IMUNON,
Inc. (Nasdaq:
IMNN), a clinical-stage
biotechnology company focused on developing DNA-mediated
immunotherapy and next-generation vaccines, reminds investors of
its virtual R&D Day event tomorrow, September 14th beginning at
4:00 p.m. Eastern time. There is no need to pre-register for the
event. A live and archived webcast will be available in the
Scientific Presentations section of IMUNON’s website or here.
Following management’s presentations, a Q&A session will be
available via the chat function of the webcast.
The Event’s Speakers
IMUNON presenters include:
- Dr. Corinne Le Goff, President and
Chief Executive Officer
- Khursheed Anwer, Ph.D., Executive
Vice President and Chief Science Officer
Guest key opinion leader presenters include:
- Sallie Permar, M.D., Ph.D., Chair
of the Department of Pediatrics at Weill Cornell Medicine and
Pediatrician-in-Chief at New York-Presbyterian/Weill Cornell
Medical Center and New York-Presbyterian Komansky Children’s
Hospital. She is also Nancy C. Paduano Professor and Chair, Weill
Cornell Medicine.
- Patrick Ott, M.D., Ph.D., Clinical
Director of the Melanoma Disease Center and the Director, Clinical
Sciences, of the Center for Immuno-Oncology at the Dana-Farber
Cancer Institute. He is also an attending physician in the
Department of Medicine at Brigham and Women's Hospital and is an
Associate Professor at Harvard Medical School.
About IMUNON
IMUNON is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlasTM,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine TM is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas TM, concerns the application of our DNA
technology to produce universal cancer vaccines, also called tumor
associated antigen cancer vaccines. The fourth modality, which is
in the discovery phase, IndiPlas TM, will focus on the development
of personalized cancer vaccines, or neoepitope cancer vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated preclinical work to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201. We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De May 2023 a May 2024